Profits rising, but no payout yet

ECO Animal Health (LSE:EAH) grew Revenue and profit in its latest financial year, ended the year with a substantial net cash balance and still proposed no dividend. The question is why the board is choosing to channel Earnings into R&D, and what that pipeline has delivered so far.

An animal health specialist

ECO Animal Health is an AIM-quoted company that develops and sells medicines and vaccines for livestock. Its established product, Aivlosin, is described by the company as its proprietary lead product and a market-leading antibiotic for respiratory and intestinal diseases in pigs and poultry, distributed to more than 70 markets. Around that core business, the group is building a portfolio of vaccines and other products, aiming to reduce its reliance on a single franchise.

Results and pipeline milestones

On 15 July 2026, ECO reported results for the year ended 31 March 2026. Revenue rose 10% to £87.5m from £79.6m, or 14% at constant currency. Gross Margin improved to 49% from 45%, adjusted EBITDA increased 16% to £8.5m, and profit before tax rose 35% to £5.4m from £4.0m. Earnings Per Share were 3.26p (2025: 2.49p) and net cash stood at £25.4m, little changed from £25.0m a year earlier despite continued investment.

The company spent £8.8m on R&D, equivalent to about 10% of revenue, and said up to nine products could receive regulatory approval within five to six years. It explained that no Dividend is proposed because profits are being reinvested in R&D, adding that it anticipates a progressive dividend policy once pipeline products generate revenue.

Two subsequent announcements illustrate that strategy. On 12 August 2026, ECO said it had taken an exclusive, perpetual licence from Vaxinano to a late-stage sheep Vaccine candidate against toxoplasmosis, a parasitic disease that causes reproductive failure. Terms include a modest upfront fee, a development milestone and royalties, funded from Operating Cash Flow within the existing R&D budget. The company estimated peak annual sales of about £10m in the UK and Europe.

Then, on 17 September 2026, ECO said the US Department of Agriculture's Center for Veterinary Biologics had accepted field safety data for ECOVAXXIN MS, its Mycoplasma synoviae vaccine for poultry, following trials in more than 170,000 laying pullets. The company said it expects US Marketing approval by the end of the calendar year. The vaccine already received EU marketing authorisation in December 2025.

Regional trading picture

Growth in the year was broad but uneven. North America revenue rose 22%, Latin America 15% and South and Southeast Asia, excluding India, 52%. China traded well over the full year but weakened in the fourth quarter as pork prices declined, while India faced distributor challenges. For the current year, management said it expects performance in line with market expectations for profitability, weighted towards the second half.

Risks to consider

The reinvestment approach carries meaningful execution risk too. Regulatory timelines can slip, and the expected US approval for ECOVAXXIN MS remains a company expectation rather than a granted licence. New vaccines must win adoption against established competitors. Aivlosin remains exposed to livestock economics, notably Chinese pork prices, and to wider scrutiny of antibiotic use in farming. Currency movements also affect reported revenue, as the gap between reported and constant currency growth in the latest year shows. Any delay to pipeline approvals would also extend the period without a dividend.

Why the cash is going into R&D

The company's stated reason is straightforward: it is using profits from Aivlosin to fund a pipeline it hopes will broaden earnings, and it has linked any future dividend to those products generating revenue. The year's results, the Vaxinano licence and the US regulatory step show that strategy being executed, although commercial returns from the pipeline are still to be demonstrated.